Display options
Cite
Bhatt-Mehta V, MacArthur RB, Löbenberg R, et al. An Algorithm to Identify Compounded Non-Sterile Products that Can Be Formulated on a Commercial Scale or Imported to Promote Safer Medication Use in Children. Pharmacy (Basel). 2015;3(4):284-294doi: 10.3390/pharmacy3040284.
Bhatt-Mehta, V., MacArthur, R. B., Löbenberg, R., Cies, J. J., Cernak, I., & Ii, R. H. P. (2015). An Algorithm to Identify Compounded Non-Sterile Products that Can Be Formulated on a Commercial Scale or Imported to Promote Safer Medication Use in Children. Pharmacy (Basel, Switzerland), 3(4), 284-294. https://doi.org/10.3390/pharmacy3040284
Bhatt-Mehta, Varsha, et al. "An Algorithm to Identify Compounded Non-Sterile Products that Can Be Formulated on a Commercial Scale or Imported to Promote Safer Medication Use in Children." Pharmacy (Basel, Switzerland) vol. 3,4 (2015): 284-294. doi: https://doi.org/10.3390/pharmacy3040284
Bhatt-Mehta V, MacArthur RB, Löbenberg R, Cies JJ, Cernak I, Ii RHP. An Algorithm to Identify Compounded Non-Sterile Products that Can Be Formulated on a Commercial Scale or Imported to Promote Safer Medication Use in Children. Pharmacy (Basel). 2015 Nov 11;3(4):284-294. doi: 10.3390/pharmacy3040284. PMID: 28975916; PMCID: PMC5597107.
Copy Download .nbib Format: NLM
Share it on

Pharmacy (Basel). 2015 Nov 11;3(4):284-294. doi: 10.3390/pharmacy3040284.

An Algorithm to Identify Compounded Non-Sterile Products that Can Be Formulated on a Commercial Scale or Imported to Promote Safer Medication Use in Children.

Pharmacy (Basel, Switzerland)

Varsha Bhatt-Mehta, Robert B MacArthur, Raimar Löbenberg, Jeffrey J Cies, Ibolja Cernak, Richard H Parrish Ii

Affiliations

  1. Department of Clinical, Social and Administrative Sciences, College of Pharmacy and Department of Pediatrics, Medical School, University of Michigan, Ann Arbor, MI, 48109, USA. [email protected].
  2. Med4Kids Research Collaborative, Ltd., Edmonton, AB, T6M 2J9, Canada. [email protected].
  3. Clinical Development, Pharmaceutics International, Inc., Hunt Valley, MD, 21031, USA. [email protected].
  4. Pharmaceutical Sciences Division, Faculty of Pharmacy and Pharmaceutical Sciences, Edmonton, AB, T6G 2R3, Canada. [email protected].
  5. Drug Discovery and Innovation Centre, University of Alberta, Edmonton, AB, T6G 2R3, Canada. [email protected].
  6. Med4Kids Research Collaborative, Ltd., Edmonton, AB, T6M 2J9, Canada. [email protected].
  7. Drexel University College of Medicine, Philadelphia, PA, 19129, USA. [email protected].
  8. St. Christopher's Hospital for Children, Philadelphia, PA, 19140, USA 8Military and Veterans' Clinical Rehabilitation Research, University of Alberta, Edmonton, AB, T6G 2G4, Canada. [email protected].
  9. Med4Kids Research Collaborative, Ltd., Edmonton, AB, T6M 2J9, Canada. [email protected].
  10. Med4Kids Research Collaborative, Ltd., Edmonton, AB, T6M 2J9, Canada.

PMID: 28975916 PMCID: PMC5597107 DOI: 10.3390/pharmacy3040284

Abstract

The lack of commercially-available pediatric drug products and dosage forms is well-known. A group of clinicians and scientists with a common interest in pediatric drug development and medicines-use systems developed a practical framework for identifying a list of active pharmaceutical ingredients (APIs) with the greatest market potential for development to use in pediatric patients. Reliable and reproducible evidence-based drug formulations designed for use in pediatric patients are needed vitally, otherwise safe and consistent clinical practices and outcomes assessments will continue to be difficult to ascertain. Identification of a prioritized list of candidate APIs for oral formulation using the described algorithm provides a broader integrated clinical, scientific, regulatory, and market basis to allow for more reliable dosage forms and safer, effective medicines use in children of all ages. Group members derived a list of candidate API molecules by factoring in a number of pharmacotherapeutic, scientific, manufacturing, and regulatory variables into the selection algorithm that were absent in other rubrics. These additions will assist in identifying and categorizing prime API candidates suitable for oral formulation development. Moreover, the developed algorithm aids in prioritizing useful APIs with finished oral liquid dosage forms available from other countries with direct importation opportunities to North America and beyond.

Keywords: compounded medications; formulation development; patient safety; pediatric

References

  1. Eur J Pharm Biopharm. 2000 Jul;50(1):3-12 - PubMed
  2. Pharm Res. 2005 Jan;22(1):11-23 - PubMed
  3. Mol Pharm. 2006 Nov-Dec;3(6):631-43 - PubMed
  4. Drug Dev Ind Pharm. 2007 Sep;33(9):909-26 - PubMed
  5. Drug Dev Ind Pharm. 2007 Oct;33(10):1043-57 - PubMed
  6. Mol Pharm. 2009 Jan-Feb;6(1):60-73 - PubMed
  7. Br J Clin Pharmacol. 2010 Nov;70(5):694-702 - PubMed
  8. AAPS J. 2012 Sep;14(3):462-72 - PubMed
  9. Clin Ther. 2012 Nov;34(11):S11-24 - PubMed
  10. ISRN Pharm. 2012;2012:436763 - PubMed
  11. Mol Pharm. 2013 Nov 4;10(11):4378-90 - PubMed
  12. Adv Drug Deliv Rev. 2014 Jun;73:102-26 - PubMed
  13. JAMA Pediatr. 2014 Feb;168(2):130-6 - PubMed
  14. Pediatrics. 2014 Mar;133(3):563-7 - PubMed
  15. Hypertension. 2014 May;63(5):1116-35 - PubMed
  16. Int J Pharm. 2014 Aug 5;469(2):251-3 - PubMed
  17. AAPS PharmSciTech. 2015 Feb;16(1):217-21 - PubMed
  18. Pharmacy (Basel). 2015 Jun 25;3(3):72-78 - PubMed
  19. Pharm Res. 1995 Mar;12(3):413-20 - PubMed
  20. Am J Health Syst Pharm. 1996 Oct 1;53(19):2304-9 - PubMed

Publication Types